NCT07060248Active, not recruiting
A Study Based on CT Radiomics for Distinguishing Benign From Malignant Renal Tumors and Assessing Their Aggressiveness.
Source: ClinicalTrials.gov · Last updated 11 Jul 2025
Brief summary (registry, in English)
To evaluate the efficacy of CT-based radiomics in differentiating benign from malignant renal tumors, predicting nuclear grading of renal cell carcinoma, and assessing T-stage of renal tumors, thereby exploring its clinical application value.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 700 (estimated)
- First submitted
- 23 Jun 2025
- Start date
- 1 Jan 2025
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Second Xiangya Hospital of Central South University
- Diseases
- Kidney cancer
- NCT number
- NCT07060248
What you commit to
- Study type: Observational
- Planned participants: 700
- From 1 Jan 2025 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Pure cystic clear cell renal cell carcinoma
- Poor-quality CT images
Who the study is looking for
- Pathologically confirmed renal tumors (including clear cell renal cell carcinoma, papillary renal cell carcinoma, chromophobe renal cell carcinoma, angiomyolipoma, and oncocytoma).
- Contrast-enhanced CT scan was performed preoperatively.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Second Xiangya Hospital Coordinator of this site? Confirm its status | Changsha | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.